Top news of the week: 15.09.2020.

#COVID19 #futurefood #futureoffood #foodtech #plantbased #biotechnology #coronavirus

Career And Jobs

On Sep 8, 2020
@IAmBiotech shared
9 biopharma leaders pledge commitment to individual safety alongside “high ethical standards and sound scientific principles” in ongoing efforts to research and develop #COVID19 vaccines and treatments. https://t.co/nqTDZaR07w
Open

Biopharma Leaders Unite to Stand with Science

Biopharma Leaders Unite to Stand with Science

The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (N

On Sep 10, 2020
@JohnCendpts shared
Phase III migraine flop sends a small-cap biotech player into a deadly tailspin $STSA - 83% https://t.co/clnvDZzHN6
Open

Phase III migraine flop sends a small-cap biotech player into a deadly tailspin

Phase III migraine flop sends a small-cap biotech player into a deadly tailspin

A small-cap player looking to cash in quickly on a reformulated drug just got flattened this morning as their one-trick pony got hit by a late-stage catastrophe. Bay Area-based Satsuma ...

On Sep 8, 2020
@BiotechWorld shared
Oncology biotech Prelude guns for $100M IPO https://t.co/47GUqmJI6H https://t.co/mSWhWYXHwq
Open

Oncology biotech Prelude guns for $100M IPO

Oncology biotech Prelude guns for $100M IPO

Fierce 15 winner Prelude Therapeutics is going for a $100 million IPO, a pretty common goal for biotechs in 2020, as it looks to finish off early clinical work for its cancer candidate ...

On Sep 9, 2020
@BiotechWorld shared
After Bind bankruptcy, Hirsch once again helms a biotech, landing at C4 https://t.co/X5UL8BwhaB https://t.co/FhXX9A25Oq
Open

After Bind bankruptcy, Hirsch once again helms a biotech, landing at C4

After Bind bankruptcy, Hirsch once again helms a biotech, landing at C4

When CEO and president at Bind Therapeutics, Andrew Hirsch had to swing the ax to his workforce, file for bankruptcy and in the end sell off its remaining assets to Pfizer.

On Sep 11, 2020
@SynBioBeta shared
Ginkgo will work with Totient, an antibody-focused startup that is just emerging from stealth mode today, to turn their alternate means of generating virus-neutralizing into a treatment that could potentially treat or temporarily prevent infection. https://t.co/4wpbLGIpTI
Open

Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody

Exclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody

Ginkgo Bioworks, with its vast warehouses of automated robots and bioreactors, has played a behind-the-scenes role in the anti-Covid fight since the start of the pandemic. They've ...

On Sep 10, 2020
@SynBioBeta shared
Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. https://t.co/Uw1o1FmwtZ
Open

Korro Bio hits the high notes with $91.5M series A to run its OPERA RNA platform

Korro Bio hits the high notes with $91.5M series A to run its OPERA RNA platform

Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases.

On Sep 8, 2020
@SynBioBeta shared
[email protected] is leveraging the power of microbe engineering and fermentation to revolutionize the future of #plantbased foods. https://t.co/mBBPdQ6asP #foodtech #futurefood #futureoffood @Ginkgo
Open

Could Fermentation Power The Future Of Plant-Based Foods? Motif FoodWorks Thinks Yes.

Could Fermentation Power The Future Of Plant-Based Foods? Motif FoodWorks Thinks Yes.

Motif FoodWorks is leveraging the power of microbe engineering and fermentation to revolutionize the future of plant-based foods.

On Sep 10, 2020
@SynBioBeta shared
A real pandemic is an awful way to put #biotechnology to the test. But that’s exactly what is happening with #coronavirus. Here are the stories of three women putting synthetic biology to use in saving lives. https://t.co/7yesYhgBsd @sives54 @janiceschen @mammothbiosci @Ginkgo
Open

Synthetic Biology Versus Coronavirus: Three Women In A Cutting-Edge Field Using Biological Engineering To Save Lives

Synthetic Biology Versus Coronavirus: Three Women In A Cutting-Edge Field Using Biological Engineering To Save Lives

A real pandemic is an awful way to put biotechnology to the test. But that’s exactly what is happening with coronavirus. Here are the stories of three women putting synthetic biology to use ...